Eton Pharmaceuticals Inc ETON.OQ ETON.O is expected to show a rise in quarterly revenue when it reports results on May 13 for the period ending March 31 2025
The Deer Park Illinois-based company is expected to report a 89.9% increase in revenue to $15.131 million from $7.97 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Eton Pharmaceuticals Inc is for earnings of 5 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $26.00, above its last closing price of $16.79.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.01 | 0.00 | -0.02 | Missed | -500.6 |
Sep. 30 2024 | -0.01 | -0.01 | 0.03 | Beat | 400 |
Jun. 30 2024 | -0.07 | -0.07 | -0.12 | Missed | -71.4 |
Mar. 31 2024 | -0.07 | -0.04 | -0.03 | Beat | 33.3 |
Dec. 31 2023 | -0.04 | -0.04 | -0.09 | Missed | -125 |
Sep. 30 2023 | -0.10 | -0.10 | -0.02 | Beat | 80 |
Jun. 30 2023 | -0.09 | -0.09 | 0.15 | Beat | 266.7 |
Mar. 31 2023 | -0.14 | -0.14 | -0.10 | Beat | 28.6 |
This summary was machine generated May 10 at 00:24 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)